Aditxt (ADTX) and The Competition Head-To-Head Review

Aditxt (NASDAQ:ADTX) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Aditxt to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for Aditxt and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1	0	0	0	1.00
Aditxt Competitors	7798	13891	25786	1038	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.71%. Given Aditxt’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Aditxt has less favorable growth aspects than its rivals.

Profitability

This table compares Aditxt and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Aditxt Competitors	-2,380.39%	-218.78%	-15.59%

Insider and Institutional Ownership

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Aditxt and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aditxt	$14,336.00	-$41.71 million	-0.00
Aditxt Competitors	$5.43 billion	$3.22 billion	553.84

Aditxt’s rivals have higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Aditxt has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Aditxt’s rivals have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.

Summary

Aditxt rivals beat Aditxt on 12 of the 13 factors compared.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.